In Vitro and In Vivo Characterization of Three Different Modes of Pump Operation When Using a Left Ventricular Assist Device as a Right Ventricular Assist Device

2014 ◽  
Vol 38 (11) ◽  
pp. 931-939 ◽  
Author(s):  
Michael C. Stevens ◽  
Shaun D. Gregory ◽  
Frank Nestler ◽  
Bruce Thomson ◽  
Jivesh Choudhary ◽  
...  
Keyword(s):  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Pump Operation ◽  
Left Ventricular Assist ◽  
Right Ventricular Assist Device ◽  
In Vivo Characterization

In Vitro and In Vivo Testing of an Implantable Motor-Driven Left Ventricular Assist Device

2008 ◽  
Vol 20 (2) ◽  
pp. 152-155 ◽  
Author(s):  
Taiji Murakami ◽  
Daiki Kikugawa ◽  
Yoshiaki Fukuhiro ◽  
Shigeo Kanazawa ◽  
Takashi Fujiwara ◽  
...  
Keyword(s):  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Left Ventricular Assist ◽  
In Vivo Testing

scholarly journals Outcome of right ventricular assist device implantation following left ventricular assist device implantation: Systematic review and meta-analysis

Perfusion ◽  
2021 ◽  
pp. 026765912110248
Author(s):  
Gregory Reid ◽  
Constantin Mork ◽  
Brigita Gahl ◽  
Christian Appenzeller-Herzog ◽  
Ludwig K von Segesser ◽  
...  
Keyword(s):  
Systematic Review ◽  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Device Implantation ◽  
Left Ventricular Assist ◽  
Right Ventricular Assist Device

Objectives: The main aim was a systematic evaluation of the current evidence on outcomes for patients undergoing right ventricular assist device (RVAD) implantation following left ventricular assist device (LVAD) implantation. Methods: This systematic review was registered on PROSPERO (CRD42019130131). Reports evaluating in-hospital as well as follow-up outcome in LVAD and LVAD/RVAD implantation were identified through Ovid Medline, Web of Science and EMBASE. The primary endpoint was mortality at the hospital stay and at follow-up. Pooled incidence of defined endpoints was calculated by using random effects models. Results: A total of 35 retrospective studies that included 3260 patients were analyzed. 30 days mortality was in favour of isolated LVAD implantation 6.74% (1.98–11.5%) versus 31.9% (19.78–44.02%) p = 0.001 in LVAD with temporary need for RVAD. During the hospital stay the incidence of major bleeding was 18.7% (18.2–19.4%) versus 40.0% (36.3–48.8%) and stroke rate was 5.6% (5.4–5.8%) versus 20.9% (16.8–28.3%) and was in favour of isolated LVAD implantation. Mortality reported at short-term as well at long-term was 19.66% (CI 15.73–23.59%) and 33.90% (CI 8.84–59.96%) in LVAD respectively versus 45.35% (CI 35.31–55.4%) p ⩽ 0.001 and 48.23% (CI 16.01–80.45%) p = 0.686 in LVAD/RVAD group respectively. Conclusion: Implantation of a temporary RVAD is allied with a worse outcome during the primary hospitalization and at follow-up. Compared to isolated LVAD support, biventricular mechanical circulatory support leads to an elevated mortality and higher incidence of adverse events such as bleeding and stroke.

In vivo testing of a pulsatile implantable impeller pump as a left ventricular assist device used in calves

Perfusion ◽  
1995 ◽  
Vol 10 (4) ◽  
pp. 257-263 ◽  
Author(s):  
KX Qian ◽  
SS Wang ◽  
SH Chu
Keyword(s):  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Left Ventricular Assist ◽  
Mean Pressure ◽  
In Vivo Testing ◽  
Serum Glutamic Oxalacetic Transaminase

A pulsatile implantable impeller pump was tested as a left ventricular assist device in five calves. The experiments lasted for 4-11 days. Death or termination was mainly due to respiratory complications or bleeding, irrelevant to the pump itself. As indicators of haemolysis, thrombogenesis, renal and hepatic functions, free haemoglobin( FHb), haematocrit (Hct), platelet number (Plt), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), creatinine, serum glutamic oxalacetic transaminase (GOT) and total bilirubin were measured preoperatively, at the beginning of the pumping (pump on), six hours later and every day thereafter. The data indicated that the pump caused no severe blood damage or organ dysfunction. Thus, the feasibility of a pulsatile centrifugal pump was demonstrated. The pump with its driver weighs 110 g and is capable of delivering a blood flow up to 8 l/min against 100 mmHg mean pressure.

A Systemic Mock Circulation for In-Vitro Testing of a Pneumatically Operated Left Ventricular Assist Device

2014 ◽  
Vol 47 (3) ◽  
pp. 8409-8414 ◽  
Author(s):  
A. Karabegovic ◽  
M. Hinteregger ◽  
C. Janeczek ◽  
W. Reichenfelser ◽  
V. Soragnese ◽  
...  
Keyword(s):  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
In Vitro Testing ◽  
Assist Device ◽  
Ventricular Assist ◽  
Mock Circulation ◽  
Left Ventricular Assist
Sign in / Sign up

Export Citation Format

Share Document